CY1118559T1 - 2,6-διαμινο-πυριμιδιν-5-υλο-καρβοξαμιδια ως αναστολεις των κινασων συκ ή jak - Google Patents

2,6-διαμινο-πυριμιδιν-5-υλο-καρβοξαμιδια ως αναστολεις των κινασων συκ ή jak

Info

Publication number
CY1118559T1
CY1118559T1 CY20161101026T CY161101026T CY1118559T1 CY 1118559 T1 CY1118559 T1 CY 1118559T1 CY 20161101026 T CY20161101026 T CY 20161101026T CY 161101026 T CY161101026 T CY 161101026T CY 1118559 T1 CY1118559 T1 CY 1118559T1
Authority
CY
Cyprus
Prior art keywords
jak
methods
syk
syk kinase
ylo
Prior art date
Application number
CY20161101026T
Other languages
English (en)
Inventor
Shawn M Bauer
Zhaozhong J Jia
Yonghong Song
Qing Xu
Mukund Mehrotra
Jack W Rose
Wolin Huang
Chandrasekar Venkataramani
Anjali Pandey
Original Assignee
Portola Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2009/002420 external-priority patent/WO2009145856A1/en
Application filed by Portola Pharmaceuticals, Inc. filed Critical Portola Pharmaceuticals, Inc.
Publication of CY1118559T1 publication Critical patent/CY1118559T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Η παρούσα εφεύρεση αναφέρεται σε ενώσεις του τύπου Ι-ΙΙ και τα φαρμακευτικά αποδεκτά ταυτομερή, άλατα, ή τα στερεοϊσομερή αυτών, τα οποία είναι αναστολείς της κινάσης Syk και/ή JAK. Η παρούσα εφεύρεση επίσης αναφέρεται σε ενδιάμεσα που χρησιμοποιούνται στην σύνθεση τέτοιων ενώσεων, την παρασκευή μίας τέτοιας ένωσης, τις φαρμακευτικές συνθέσεις που περιέχουν μία τέτοια ένωση, τις μεθόδους αναστολής της δραστικότητας της κινάσης Syk και/ή JAK, τις μεθόδους αναστολής της συσσωμάτωσης των αιμοπεταλίων, και τις μεθόδους για την πρόληψη ή τη θεραπεία ενός αριθμού παθήσεων που προκαλούνται τουλάχιστον εν μέρει από την δραστικότητα της κινάσης Syk και/ή JAK, όπως η καρδιαγγειακή νόσος, η φλεγμονώδης νόσος, η αυτοάνοση νόσος και η πολλαπλασιαστική διαταραχή κυττάρων, η θρόμβωση, η αλλεργία, το άσθμα, η ρευματοειδής αρθρίτιδα, η λευχαιμία, ή το λέμφωμα μη-Hodgkin.
CY20161101026T 2008-04-16 2016-10-13 2,6-διαμινο-πυριμιδιν-5-υλο-καρβοξαμιδια ως αναστολεις των κινασων συκ ή jak CY1118559T1 (el)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US4541708P 2008-04-16 2008-04-16
US4540608P 2008-04-16 2008-04-16
US4539908P 2008-04-16 2008-04-16
US12034108P 2008-12-05 2008-12-05
US12034808P 2008-12-05 2008-12-05
US12034408P 2008-12-05 2008-12-05
PCT/US2009/002420 WO2009145856A1 (en) 2008-04-16 2009-04-16 2, 6-diamino-pyrimidin- 5-yl-carboxamides as syk or jak kinases inhibitors

Publications (1)

Publication Number Publication Date
CY1118559T1 true CY1118559T1 (el) 2017-07-12

Family

ID=43570275

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161101026T CY1118559T1 (el) 2008-04-16 2016-10-13 2,6-διαμινο-πυριμιδιν-5-υλο-καρβοξαμιδια ως αναστολεις των κινασων συκ ή jak

Country Status (18)

Country Link
AU (1) AU2009251863B2 (el)
BR (1) BRPI0910560B8 (el)
CO (1) CO6331433A2 (el)
CY (1) CY1118559T1 (el)
DK (1) DK2321283T3 (el)
ES (1) ES2597441T3 (el)
GT (1) GT201000298A (el)
HK (1) HK1158179A1 (el)
HU (1) HUE031638T2 (el)
IL (3) IL208637A (el)
LT (1) LT2321283T (el)
MX (1) MX353206B (el)
NI (1) NI201000176A (el)
NZ (1) NZ589314A (el)
PL (1) PL2321283T3 (el)
PT (1) PT2321283T (el)
SI (1) SI2321283T1 (el)
ZA (1) ZA201007045B (el)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013202496B2 (en) * 2008-06-27 2016-08-04 Celgene Car Llc Heteroaryl compounds and uses thereof
BRPI0914682B8 (pt) 2008-06-27 2021-05-25 Avila Therapeutics Inc compostos de heteroarila e composições compreendendo os referidos compostos
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
KR20130099040A (ko) 2010-08-10 2013-09-05 셀진 아빌로믹스 리서치, 인코포레이티드 Ｂｔｋ 억제제의 베실레이트 염
US9145387B2 (en) 2013-02-08 2015-09-29 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
US10005760B2 (en) 2014-08-13 2018-06-26 Celgene Car Llc Forms and compositions of an ERK inhibitor
CN114196651B (zh) * 2021-12-15 2023-06-30 中国林业科学研究院亚热带林业研究所 D6蛋白激酶d6pkl2的新用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1507199A (en) * 1997-12-15 1999-07-05 Yamanouchi Pharmaceutical Co., Ltd. Novel pyrimidine-5-carboxamide derivatives
EP1518855B1 (en) * 2002-06-28 2011-10-26 Astellas Pharma Inc. Diaminopyrimidinecarboxa mide derivative
EP2046759A1 (en) * 2006-07-21 2009-04-15 Novartis AG 2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as jak kinases inhibitors

Also Published As

Publication number Publication date
IL208637A0 (en) 2010-12-30
BRPI0910560B1 (pt) 2023-01-24
NI201000176A (es) 2011-08-08
DK2321283T3 (en) 2016-10-31
IL251655B (en) 2020-05-31
PT2321283T (pt) 2016-10-19
ES2597441T3 (es) 2017-01-18
MX353206B (es) 2018-01-08
AU2009251863A2 (en) 2011-06-09
AU2009251863B2 (en) 2014-09-25
IL251655A0 (en) 2017-06-29
MX2010011464A (es) 2014-06-16
GT201000298A (es) 2014-05-07
PL2321283T3 (pl) 2017-01-31
AU2009251863A1 (en) 2009-12-03
NZ589314A (en) 2012-10-26
ZA201007045B (en) 2012-08-29
CO6331433A2 (es) 2011-10-20
BRPI0910560B8 (pt) 2023-03-21
IL274522A (en) 2020-06-30
HK1158179A1 (zh) 2012-07-13
BRPI0910560A2 (pt) 2021-04-27
HUE031638T2 (en) 2017-07-28
SI2321283T1 (sl) 2017-01-31
IL208637A (en) 2017-04-30
LT2321283T (lt) 2016-12-12

Similar Documents

Publication Publication Date Title
CY1118559T1 (el) 2,6-διαμινο-πυριμιδιν-5-υλο-καρβοξαμιδια ως αναστολεις των κινασων συκ ή jak
CY1119771T1 (el) Ενωσεις αμινοπυριμιδινυλιου ως αναστολεις toy jak
CY1126044T1 (el) Πυραζολο[1,5-αλφα]πυριμιδινες χρησιμες ως αναστολεις της κινασης atr για την αντιμετωπιση καρκινικων νοσων
CY1122046T1 (el) Δικυκλικα ετεροκυκλικα παραγωγα ως αναστολεις βρομοτομεων
MY155639A (en) 2, 6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinases inhibitors
CY1121433T1 (el) Παραγωγα δικυκλικων ετεροκυκλυλιων ως αναστολεις irak4
CY1119004T1 (el) Διϋδροπυριδονη p1 ως αναστολεις τελεστη χια
CY1119678T1 (el) Πυριμιδινονες ως αναστολεις τελεστη χια
CY1111203T1 (el) 4-ανιλινοκινολινο-3-καρβοξαμιδια ως αναστολεις κινασης csf-1r
CY1113324T1 (el) Υποκατεστημενα αμιδικα παραγωγα ως αναστολεις πρωτεϊνικων κινασων
CY1122601T1 (el) Αναστολεις gsk3 και μεθοδοι χρησης αυτων
EA201891091A1 (ru) Соединения ингибитора jak киназы для лечения респираторного заболевания
EA201890888A1 (ru) Новые спиро[3h-индол-3,2'-пирролидин]-2(1h)-оновые соединения и производные в качестве ингибиторов mdm2-p53
CY1118128T1 (el) Αρυλ διϋδροπυριδινονες και πιπεριδiνονες ως αναστολεις του mgat2
EA201992126A1 (ru) Ингибиторы jak, содержащие 4-членный гетероциклический амид
EA201592199A1 (ru) Производные бипиразола в качестве ингибиторов jak
MX2013012776A (es) Inhibidores de la tirosina cinasa de bazo que contienen aminopiridina.
EA201991884A2 (ru) Ингибиторы g12c kras
CY1118093T1 (el) Φαρμακοτεχνικες μορφες που περιλαμβανουν παραγωγα 1-(bhta-d-γλυκοπυρανοζυλ)-2-θειενυλμεθυλβενζολιου ως αναστολεις sglt
CY1122182T1 (el) Ανοσοκατασταλτικες φαρμακοτεχνικες μορφες
EA200870117A1 (ru) Азаиндоловые ингибиторы аурора-киназ
EA201290324A1 (ru) Киназные ингибиторы
EA201492170A1 (ru) Новые замещенные в цикле n-пиридиниламиды в качестве ингибиторов киназ
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
EA201291246A1 (ru) Конденсированные бициклические ингибиторы киназы